ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
ProMIS Neurosciences licensed TXP1, a transferrin receptor 1 (TfR1)-targeting brain-selective shuttling technology, from Ossianix for use with its lead Alzheimer's antibody PMN310. In Ossianix preclinical studies, including non-human primate work, TXP1 increased antibody delivery to the brain by more than 65-fold with no off-target accumulation in major organs reported. ProMIS holds options to extend TXP1 to PMN442 (alpha-synuclein/Parkinson's) and PMN267 (TDP-43/ALS), and says the deal does not change its disclosed cash runway through 2027.
Key figures
- Cash runway
- through 2027
- Brain delivery increase
- more than 65-fold
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.